Tryton dedicated bifurcation stent in treatment of unprotected distal left main bifurcation disease.
CARDIOVASCULAR REVASCULARIZATION MEDICINE 2018;
19:60-64. [PMID:
29793898 DOI:
10.1016/j.carrev.2018.05.003]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2018] [Revised: 04/14/2018] [Accepted: 05/02/2018] [Indexed: 11/20/2022]
Abstract
Percutaneous coronary interventions involving coronary bifurcation lesions are more complex and associated with adverse outcomes (both angiographic and clinical) compared to non-bifurcation lesions. Tryton, a dedicated bifurcation stent, has been introduced with the aim to simplify treatment of bifurcation lesions. Tryton stent in combination with conventional drug eluting stent is safe and associated with reduced stenosis and bail-out stenting of side branch compared to provisional stenting involving a large side. However, little is known regarding safety and efficacy of Tryton stent in left main (LM) bifurcation lesion. We describe two cases of unprotected LM bifurcation stenting using Tryton stent in combination with drug eluting stent.
Collapse